DK0933995T3 - Fremgangsmåde til behandling af endotelskader - Google Patents

Fremgangsmåde til behandling af endotelskader

Info

Publication number
DK0933995T3
DK0933995T3 DK97940974T DK97940974T DK0933995T3 DK 0933995 T3 DK0933995 T3 DK 0933995T3 DK 97940974 T DK97940974 T DK 97940974T DK 97940974 T DK97940974 T DK 97940974T DK 0933995 T3 DK0933995 T3 DK 0933995T3
Authority
DK
Denmark
Prior art keywords
procedure
treatment
endothelial damage
epo
endothelium
Prior art date
Application number
DK97940974T
Other languages
Danish (da)
English (en)
Inventor
Athanasius A Anagnostou
George Sigounas
Original Assignee
Univ East Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24861777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0933995(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ East Carolina filed Critical Univ East Carolina
Application granted granted Critical
Publication of DK0933995T3 publication Critical patent/DK0933995T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • External Artificial Organs (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK97940974T 1996-09-11 1997-09-10 Fremgangsmåde til behandling af endotelskader DK0933995T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/712,358 US20020052309A1 (en) 1996-09-11 1996-09-11 Method of treating endothelial injury
EP97940974A EP0933995B8 (en) 1996-09-11 1997-09-10 Method of treating endothelial injury

Publications (1)

Publication Number Publication Date
DK0933995T3 true DK0933995T3 (da) 2005-02-14

Family

ID=24861777

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97940974T DK0933995T3 (da) 1996-09-11 1997-09-10 Fremgangsmåde til behandling af endotelskader

Country Status (11)

Country Link
US (5) US20020052309A1 (enExample)
EP (1) EP0933995B8 (enExample)
JP (3) JP2001503028A (enExample)
CN (2) CN1113669C (enExample)
AT (1) ATE282425T1 (enExample)
CA (1) CA2265547C (enExample)
DE (1) DE69731652T2 (enExample)
DK (1) DK0933995T3 (enExample)
ES (1) ES2231889T3 (enExample)
PT (1) PT933995E (enExample)
WO (1) WO1998010650A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
IL124015A0 (en) 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
FR2786104B1 (fr) * 1998-11-25 2002-12-27 Centre Nat Rech Scient Inhibiteurs de l'activation de nf-kb, et leurs utilisations pharmaceutiques
US7309687B1 (en) * 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
TR200103785T2 (tr) * 1999-04-13 2002-06-21 The Kenneth S. Warren Institute, Inc. Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi
US6171620B1 (en) * 1999-04-27 2001-01-09 Health Research, Inc. Method of enhancing the efficacy of anti-tumor agents
WO2000067776A1 (en) * 1999-05-11 2000-11-16 Ortho-Mcneil Pharmaceuticals, Inc. Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
US20030152562A1 (en) * 2001-10-23 2003-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Vitro micro-organs, and uses related thereto
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US20020061849A1 (en) * 2000-05-02 2002-05-23 Soren Nielsen Methods for treatment of diseases associated with inflammation under non-ischemic conditions
DE60131393D1 (de) * 2000-05-02 2007-12-27 Action Pharma As Verfahren zur behandlung von erkrankungen assoziiert mit akuten entzündung unter nichtischämischen zustände
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
EP1930023A3 (en) * 2001-04-09 2008-08-06 East Carolina University Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
US20020169128A1 (en) * 2001-04-09 2002-11-14 Geroge Sigounas Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
WO2002097038A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
DK1459762T3 (da) * 2001-11-02 2008-10-06 Yoshiko Yasuda Anvendelse af EMP9 til forebyggelse af proliferative organsygdomme
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
GB0211578D0 (en) * 2002-05-21 2002-06-26 Univ Belfast Medicaments
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
CN1897959A (zh) * 2003-09-29 2007-01-17 沃伦药品公司 用于治疗和预防脓毒病和粘连形成的组织保护细胞因子
WO2005094236A2 (en) * 2003-11-07 2005-10-13 Henry M. Jackson Foundation Activation of hypoxia-inducible gene expression
DE102004004509B4 (de) * 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
WO2005099773A1 (en) * 2004-04-05 2005-10-27 University Of Vermont And State Agricultural College Use of erythropoietin for treatment of cancer
US20110076255A1 (en) * 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
WO2008050836A1 (en) * 2006-10-25 2008-05-02 Ajinomoto Co., Inc. Agent for ameliorating adverse side-effect of chemotherapeutic agent
RU2426174C1 (ru) * 2010-03-29 2011-08-10 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ фармакологической коррекции ишемии конечности, в том числе при l-name индуцированном дефиците оксида азота
US9533010B2 (en) * 2011-10-31 2017-01-03 Amorcyte, Llc Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
CN105189556A (zh) * 2013-03-15 2015-12-23 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法
EP4340865A4 (en) * 2021-05-18 2025-04-02 Attias, Eyal USE OF ERYTHROPOIETIN (EPO) OR ERYTHROPOIESIS STIMULATING AGENT (ESA) FOR THE TREATMENT OF OSTEOMYELITIS, BONE INFECTION AND BONE INFLAMMATION

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045849B2 (ja) * 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
US5002755A (en) * 1988-02-18 1991-03-26 Vanderbilt University Method of controlling nephrotoxicity of anti-tumor plaintum compounds
JP2632014B2 (ja) * 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
JPH0782174A (ja) * 1993-09-17 1995-03-28 Takeda Chem Ind Ltd 抗腫瘍剤
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
JP2001520503A (ja) * 1994-12-30 2001-10-30 カイロン コーポレイション インビボにおける固形腫瘍の処置のための方法および組成物
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions

Also Published As

Publication number Publication date
CN1250281C (zh) 2006-04-12
JP2001503028A (ja) 2001-03-06
DE69731652D1 (de) 2004-12-23
EP0933995A1 (en) 1999-08-11
EP0933995B1 (en) 2004-11-17
CN1235512A (zh) 1999-11-17
CN1429623A (zh) 2003-07-16
HK1022810A1 (en) 2000-08-25
US7531501B1 (en) 2009-05-12
ATE282425T1 (de) 2004-12-15
CN1113669C (zh) 2003-07-09
CA2265547C (en) 2009-12-01
US7803408B2 (en) 2010-09-28
JP2008133305A (ja) 2008-06-12
JP2009196999A (ja) 2009-09-03
EP0933995A4 (en) 2002-08-28
US20090285908A1 (en) 2009-11-19
WO1998010650A1 (en) 1998-03-19
CA2265547A1 (en) 1998-03-19
DE69731652T2 (de) 2005-12-15
US20020052309A1 (en) 2002-05-02
ES2231889T3 (es) 2005-05-16
US5922674A (en) 1999-07-13
US20080124401A1 (en) 2008-05-29
PT933995E (pt) 2005-02-28
EP0933995B8 (en) 2005-01-19

Similar Documents

Publication Publication Date Title
PT933995E (pt) Metodo para tratamento de lesao endotelial
DE60026538D1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
PT927150E (pt) Compostos de lipoxina e sua utilizacao no tratamento de doencas proliferativas celulares
DK0725637T3 (da) Parenteralt busulfan til behandling af malign sygdom
ES2071484T3 (es) Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral.
ES2074867T3 (es) Derivados de quinazolina para potenciar la actividad antitumoral.
GB0013674D0 (en) Therapeutic use
ES2191192T3 (es) Tienopirimidinas.
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
DE69834923D1 (en) Hochgradig lipophile camptothecin-derivate
KR950700749A (ko) 2'-할로메틸리덴 유도체와 S-기 또는 M-기 특이성 항종양제를 사용하는 결합치료에 의한 암치료 방법(Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a S-phase or M phase specific antineoplastic agent)
ES2049690T1 (es) Derivados de taxano, su preparacion y uso en oncologia.
WO2000040229A3 (en) Synergistic tumorcidal response induced by histamine
ES2068714T3 (es) Derivados de pirimidina para aumentar la actividad antitumoral.
AU3401093A (en) Therapeutic agent for threatened abortion
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
DE60232154D1 (de) Prophylaktische und therapeutische verwendung von hydroxysteroiden
GB9004348D0 (en) New use of catechol derivatives and their physiologically acceptable salts and esters
BG101145A (bg) Използване на /s/-аденозил-l-метионин /саме/ i неговите физиологично съвместими соли за лечение нареперфузионно увреждане, причинено от временна фокална исхемиа
WO2001022976A3 (en) Combination of a statin and ex-vivo treated blood for treating artheroclerosis
GEP20043220B (en) S-Nitrosothiols as Agents for The Treatment of Circulatory Dysfunctions
DK1150981T3 (da) Terapeutisk necleosidforbindelse
DK0455769T3 (da) Anvendelse af 7-OH-1,2-benzopyron til fremstilling af et lægemiddel til behandling af magline tumore r hos mennesker
MX9203715A (es) Preparciones para el tratamiento del tejido aloinjertado.
IT1264428B1 (it) Composizioni farmaceutiche per il trattamento della psoriasi